39 search results for: COPD

Exacerbations Lead to Worsening Lung Function
expert video

Exacerbations Lead to Worsening Lung Function

Type 2 Inflammation
Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.
View more
ERS 2024 | IL-33 A Promising Target
expert video

ERS 2024 | IL-33 A Promising Target

Pulmonology
Professor Klaus Rabe presents the latest clinical data on current and emerging biologic therapies targeting IL-33 in COPD.
View more
ERS 2024 | What Do We Know About IL-33 Genetics?
expert video

ERS 2024 | What Do We Know About IL-33 Genetics?

Pulmonology
Dr. Stephanie Christenson examines the genetic and environmental factors influencing IL-33 expression and activity in COPD, highlighting the complex interplay between genetics, smoking, and disease pathogenesis.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region